-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AB5GLHxUCD6CMx1ygSND72a2GDFM/PCL+E5tuALfVCXvKzObjaAxICHVQecrJbvR
 a/N3XMlBeQ8IUGyb2c2Eww==

<SEC-DOCUMENT>0000950123-09-044977.txt : 20090923
<SEC-HEADER>0000950123-09-044977.hdr.sgml : 20090923
<ACCEPTANCE-DATETIME>20090922203433
ACCESSION NUMBER:		0000950123-09-044977
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090923
DATE AS OF CHANGE:		20090922

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-148572
		FILM NUMBER:		091081728

	BUSINESS ADDRESS:	
		STREET 1:		1420 5TH AVE
		STREET 2:		SUITE 2600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-623-4688

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OMEROS CORP
		CENTRAL INDEX KEY:			0001285819
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		1420 5TH AVE
		STREET 2:		SUITE 2600
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-623-4688
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>f35568fpfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML>
<HEAD>
<TITLE>fwp</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Filed Pursuant to Rule&nbsp;433<BR>
Issuer Free Writing Prospectus dated September&nbsp;22, 2009<BR>
Relating to Preliminary Prospectus dated September&nbsp;16, 2009<BR>
Registration No.&nbsp;333-148572
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f35568fpf3556846.gif" alt="(OMEROS LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 36pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This free writing prospectus relates only to the shares of common stock described below and
should be read together with the preliminary prospectus dated September&nbsp;16, 2009 relating to this
offering (the &#147;<B>Preliminary Prospectus</B>&#148;), included in Amendment No.&nbsp;5 to the Registration Statement
on Form S-1 (File No.&nbsp;333-148572) relating to these securities. The most recent amendment to the
Registration Statement can be accessed through the following link:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
<U>http://sec.gov/cgi-bin/browse-edgar?action=getcompany&#038;CIK=0001285819&#038;owner=exclude&#038;count=40</U> </DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All references in this free writing prospectus to &#147;Omeros,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Omeros
Corporation and its subsidiary. The following information supplements and updates the information
contained in the Preliminary Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>The disclosure set forth in the Preliminary Prospectus under &#147;Risk Factors &#151; Our former chief
financial officer has made allegations against us that may lead to litigation.&#148; has been updated to
read in substance as follows:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Our former chief financial officer has filed a lawsuit against us and our current and former
directors, the defense of which may consume our time and resources, harm our reputation and the
reputations of our current and former directors, and materially negatively affect our financial
position and cause our stock price to decline.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2008, our former chief financial officer, Richard J. Klein, used our Whistleblower
Policy procedures to report to the chairman of our audit committee that we had submitted grant
reimbursement claims to the National Institutes of Health, or NIH, for work that we had not
performed. In accordance with the Whistleblower Policy and its charter, our audit committee, with
special outside counsel, commenced an independent investigation of our NIH grant and claims
procedures. The investigation concluded that we had not submitted claims to the NIH for work we had
not performed. In January&nbsp;2009, we terminated Mr.&nbsp;Klein&#146;s employment for reasons other than this
incident. Mr.&nbsp;Klein alleged that he was wrongfully terminated and claimed it was retaliatory. We
subsequently voluntarily reported to the NIH Mr.&nbsp;Klein&#146;s whistleblower report and the audit
committee findings; the NIH confirmed to us in writing that it was satisfied with our handling of
these grant matters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;21, 2009, Mr.&nbsp;Klein filed a lawsuit against us and our current and former
directors in the United States District Court for the Western District of Washington, alleging,
among other things, that we violated the Federal False Claims Act, wrongfully discharged his
employment in violation of public policy and defamed him. Mr.&nbsp;Klein seeks, among other things,
damages in an amount to be proven at trial, actual litigation expenses and his reasonable
attorneys&#146; fees and damages for loss of future earnings. Although we have been advised by outside
employment and corporate counsel that we have meritorious defenses to Mr.&nbsp;Klein&#146;s allegations, and
we intend to defend ourselves vigorously, neither the outcome of the litigation nor the amount and
range of potential damages or exposure associated with the litigation can be assessed with
certainty. Further, defending this lawsuit may consume our time and resources, harm our reputation
and the reputations of our current and former directors, and materially negatively affect our
financial position and cause our stock price to decline.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>The disclosure set forth in the Preliminary Prospectus under &#147;Business&#151;Legal Proceedings&#148; has been
updated to read in substance as follows:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;29, 2008 we filed a complaint, now pending in U.S. District Court for the Western
District of Washington, against Scottish Biomedical, Ltd., a United Kingdom private limited
company, related to contract laboratory services provided by Scottish Biomedical for our PDE10 and
PDE7 programs. In our
complaint, we allege that Scottish Biomedical breached our contract laboratory services
agreement, committed fraud and misrepresentations and fraudulent concealment and violated the
Washington Consumer Protection Act. Our complaint seeks unspecified damages resulting from our
having to re-perform certain services provided by Scottish Biomedical and for losses we suffered as
a result of delays to the advancement of our programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;21, 2009, our former chief financial officer, Richard J. Klein, filed a lawsuit
against us and our current and former directors in the United States District Court for the Western
District of Washington. Mr.&nbsp;Klein alleges in his complaint that we, among other things, violated
the Federal False Claims Act, wrongfully discharged his employment in violation of public policy
and defamed him. Mr.&nbsp;Klein seeks, among other things, damages in an amount to be proven at trial,
actual litigation expenses and his reasonable attorneys&#146; fees and damages for loss of future
earnings. On September 22, 2009, we filed with the court our answer to Mr.&nbsp;Klein&#146;s allegations, generally denying
his claims and bringing counterclaims against Mr.&nbsp;Klein for breach of contract, misappropriation of
trade secrets and breach of fiduciary duty. We intend to vigorously defend ourselves against Mr.
Klein&#146;s claims and to seek, among other things, our attorney&#146;s fees and costs incurred in defending
this action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2008, Mr.&nbsp;Klein used our Whistleblower Policy procedures to report to the chairman
of our audit committee that we had submitted grant reimbursement claims to the National Institutes
of Health, or NIH, for work that we had not performed. In accordance with the Whistleblower Policy
and its charter, our audit committee, with special outside counsel, commenced an independent
investigation of our NIH grant and claims procedures. The investigation concluded that we had not
submitted claims to the NIH for work we had not performed. In January&nbsp;2009, we terminated Mr.
Klein&#146;s employment for reasons other than this incident. We subsequently voluntarily reported to
the NIH Mr.&nbsp;Klein&#146;s whistleblower report and the audit committee findings; the NIH confirmed to us
in writing that it was satisfied with our handling of these grant matters. Although we deny Mr.
Klein&#146;s allegations and believe that we have substantial and meritorious defenses to his claims,
neither the outcome of the litigation nor the amount and range of potential damages or exposure
associated with the litigation can be assessed with certainty.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>The issuer has filed a registration statement (including a prospectus) with the SEC for the
offering to which this communication relates. Before you invest, you should read the prospectus in
that registration statement and other documents the issuer has filed with the SEC for more complete
information about the issuer and this offering. You may get these documents for free by visiting
EDGAR on the SEC Web site at </B><B><I>www.sec.gov</I></B><B>. Alternatively, the issuer, any underwriter or any dealer
participating in the offering will arrange to send you the prospectus if you request it by calling
Deutsche Bank Securities Inc. toll-free at 1-800-503-4611 or by sending an email to Deutsche Bank
Securities Inc. at prospectusrequest@list.db.com.</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>f35568fpf3556846.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f35568fpf3556846.gif
M1TE&.#EAK@!T`.8``/WTZKO"T8F7L9*>M_[Y\_KBR^WM\?W]_=K<Y<+*V$1:
MA*JSQEAKD;2[S.V+.O?-I?"=65%FC>/EZRA#<G6$H^M[(NIU&4IABO&C9.^4
M2OCX^?*L=.IQ$X21K>R!+/G:O*2MP>EE`_G>P_*J;/.S>FI[G.R%,?"A7?'Q
M]/2[BSE1?</(UO7!E)FDNV)SE_;$FOOET?C4M&5WF>EI"?*G:\W1W/SRYC-+
M>?2YA.EL#7V,J>Z21=;9XN^94>GJ[][@Z/[\^H&-J?2V@\G.VA,Q9J&IOO?0
MK1PY:_*P=-#4WOOKVAHV:OSMWB(];^V(-O3T]Y6AN?;V^.MX'<#&U'J)IOSN
MX/6]D.Z/0]/6X/;)G#Y5@/WW\.^83>IO$/3`B^Q_*)ZHO6=XFOOHUKB_S^EH
M!GB'I5YPE!8T://S]N_P\Y:@M_[[]_.X?0\O9!`O9?O[_/SKV.;G[7"!H?#P
M\^V//FY_GZ^VR/SLVOOLVOOKW/"H8\?+U^EK"^ED`0XN9/___R'Y!```````
M+`````"N`'0```?_@'^"@X2%AH>(B8J+A1LBC)"1DI.4E9:7F(9B%E>9GI^@
MH:*?&WTA-J.IJJNLEEL6?7TTK;2UMJM"L7TY6[>^O\"0:QRZ?0_!R,G!+,5]
M%0?*T=*J!#G-?3'3VMN8+]=])-SBXXL'7]\GY.KK@C'??2\O[//;6T[?#E9=
M0/3]RD8AKH408Z(/$G\(@4&X1N;$@UA2H"6<V$J)-5TS0DA1<B]6`8H@5972
M53`$"1C%TH5<^6D+&5TO0W2QX:"9&)8X+R$I5A(#RF;A<@J-]$I7%PMD,HCP
MUNQ+E4/\ADK]XTY7A3Y.7AQ0$K"9E4%;1%B!<,7(5*$',L0*,<-#GPTP_P1=
MN>9D38P3,W+P"3CK+,X/Q:3TD2)DT,]FQ%["'.$7YXAB&4V@&N2V6==F&QJO
M_'#1U"X<A9B]:]97,T4:EDT`*&2CR^ABI4TC)""X6`46A0A<(39:(QW<LA..
MS&$M!`0\A(!X<'+N&A\+4O1XR<(D>,*K?6KN<D!H388OM:_-.$$'AY(#&[I4
MN++AIG5U1G2YG9$AFR`@2,"_1M)+$&J8#KRPQGO<'%!0+&1P(`4.!!CVQ1>7
MH2/1'_\5$T(&<1$XS6%]%.2`68*D!6&$UW3QB'_OA&"?ALJ,5($##EA`1X."
M?%"!!Z[I`LLUI57($'`L!@/$94YP\,4Q@_1P%/]D.82G"P>#^"@>B$'^\H%K
M"3IA00]1_6&$"62$T-4,73@`PPS7@/:'$!7P,9H%JU5YRQI>W,/!#B9`D`(A
MWXG9A9AD=)&-6DT)0H`-!;R`P8ZDR7E+`2>80D8/)HQ`XQ];=)&#F,Z0,0,&
M@F1!8A\?%;(%"9VM-9FCK11PX`@Y9`"J81R$8((4.9Q@@04G$J!=,4X@8D-S
MN@#)ZBHD)&@!%S/0\=0@1M3TQ:85=''"@(*(UHP2B*SQ:X?'LE+%.7SHP4<%
M:@[R@@4SF$#F#%)\0(@-J<:2&2+V%!-GN*,D:T$7>G1XXB!6Y-#L#!7D\$5_
M@^1BV:J&B)!C'QGR&XK_MZ9DT`4'2$R8+9@C2%$!!PYT*4@5WWR5R$BD6BR*
M$7QP8,%C0NRK+AW928'C08;,U8P3#!L"F$<NAU)3"#L@[%XA,4"`]!<6\)$N
M(04()`\B!"A67=&>5!&F%/?P=T@>7%B0P0Y?\%&8(>9<DX$B5^W#M2>Y/*=1
MT,E!S1P'.=QKB`UP!"[X'8H4%-O<E0`P@P4AL"N"QX44V4,/4LP,R@%NRHOX
M)3B(68$4+%QZR`L95'#"Y'2`(D8?%D"^>20$X,E'='`LLL4(#NR`Q!4C0'P)
M"R%H_CHE5EA@@@=??."Z(3BP00<2%;!1*B:Q<S&\)5R0_($7OB,"Q`,0G.``
M_PF/9\*""29?#PD,)NR0@@WI*X(#"2?HX8`(W4O"1`_YJZ\(!B;H@A%LQ@@"
ML(`$64`"!@C(B`]L@`8GD`($1@`!#-!@`P^D0?AH0`,,8&`#+_C`%D0W-^5P
MX`3+LQT&($`"'"!)$BEXS3L<\``;8&MX(J@`'99&"0*<C@0LJ!@D8BA#!'7!
M`W38P`-B``,`I-!B/<A`"I[(B`.D@`X[.$G\$$'$WGC."3UX0!5LL`4J\HLV
M+]@B):K@A1.0(`;/6D07OZ$7A&7@!&SP0@&RP,"Y%<`"),0$$)1``CV,@`5,
MB.,AYG@-"4I'!%L``MY>=P`,4$D18N"@)C?)20Z>;O\'7+@"#?KX!T;JP@E.
MR$`68O``$<!`"6J<&P%(<$-%K&$#HRKB8+BUR'=P@$Q<P,`'2/DZ&VPM$E9`
MDRX#PTM#/,`#4C!!#R"P@QWT``,9Z$'Y_/<)(TQLF1OAYH9X`\YFBE,95>B(
M+L-Y3FG8P&=%9&<[I;&0>)ISGOC,IS[WR<]^^O.?``VH0`=*T((:]*`(3:A?
M##`%$/`@``L8`AKFX8,`M$```FA!`%"@#`.L``13V`,8IN"#3%14`!$(@B$T
M`((2E"``;T#$$+30!C_XH0@7L"D1&!"'2"C`#7Z8``@B$8<C-&$"2]!")'YP
M`:#:]*EM8,`/$,&`)1QA`EC_;<(2MMH$!72@I)3@05-M2H$@V-0-"N!!)7[P
MTZ?Z80R%Z,!%QR"``1CB!Q%P*Q$6P`"WNJ$#9OR#"MPZ!4CT]:DJ8(0&Y%#3
MI][`!1<@@DTG,%5#Y-2MF-6I2B/A`Q?HM0,#P*P+HA`)"9C!K4OH0`#`*H@?
M4"`):G#!$,I0B!5,P+%VX.@?]J``MX;!`(L8[%,G,(=%Q$&RB%V$!`[K!S<P
MH`:#>$(#(D#90S#7#P(PP`\6<-FG4B"FBTB"<(-:!.#^@0?7C4!E%;&"&PQW
M`.8M!!:HD`0S:&$.FQ4$`FYKTR8@H!!LA2H%@HM9.RP"!)A-K"(\^]0PI,$0
M3QA`_T\-<5V["N()IW4K7!5A`/?:]`Q[*(0/,FQ3,U!1`OP-Z@H2@08*[`$$
M%`"!#@:!AB:X=0B'J$%C;=H`18S7IC)0Q`%^[`<%(R*TPWWP)"I<B!]?X`F)
M>(,6W`J&0\1A"6[-+]NF;-,V0%<10V!``!K@@O\*H@QNC4`BT/S4)H#W$$3V
M;R*PD-D+)`(%9W!KCRG!9$*`P:UMV/,A6N#6&R2B"'J-;R$"D&9(O`$+/)C0
M"C!;6$3P`+,"2$1WGUKE(]<Y$25PZQ$T4(D^#V*_;NT`(GZ`7)NJX<Y.M:D+
MJ.K6H5;B#3(H]")2[(<FD/H0FY8U(C205\S:^1`^:+4?ZO]@"0;;U,*#>,.F
M@WP(LS[U"%!.1+%URMI!H$#9BI9$#6S\U!(L@@J8#3&P,SL!1-3@")\^Q`(P
MB^-*Y/JIT!Z$L_W``"M[V*;'3L2\W;H`0R``L[^F1`<PVX)%U`"S6B9$L&VZ
MX4(@V=B(V'9S26MOM^9;$/>V:;\-@6BWSE@1/L"LF@N1A'1;HK=/=<.*%?$$
MS#9A>9?]MQ]F36&;:CS@A$BY6]MMB9#[X>-_V+>Y#;'OFS("WF[M]A_H[-8!
M4^(->1[N>A-![J>:N1"7E</0#?$&+!-!#6X%^B`8G?9+&!WI&L^T(71.A`0P
M`N9/#8"(;1[80C0`LPI(>"*X_-3_BDO<IG90]M<%\6<_7*#DPC8$%#!K!K=[
MO!"HMND2[%X(`\0ZJ(NGM5L;WF3,(GT1"W?KR!>A<3^0'NPV3<!U3SZ(PPX`
M\CL_!+K=*@?+X[L0"]@Q`P0O"#M@5@NZ542HLVP(0KOU##./1-.7O@@2VU35
MEHV]\8=+B`/`>PE1P#W/"]%TVE/B[86XKMX-D?JGKGP1;&ZP(9*-V0FHV["8
MM?HBC.X'_1_>#PD@=$^E5H+0<OSV!^)W"*TG=QWW>X-@!SO&@(50!YBU>HH@
M`!5X"!B(64>0!)$0;!*8"/Q';;`'@((U>H,0!C8%!0CH5N/W?T_5`BU``318
M@W(@`S+`_P`%=PCH)P@@D'5^H`-O5@@C"`D;^%1J%R*$]U1G4&F+@'<V%8*(
M4(399X(Z4&@Q]0;P-@'_E8"%D`9$AE.9Y592"'(>EP9!0'@78'@]YUM&B'&'
M(`%$Y@=GP(;K1H:00(4E:'<\\'EJ=6D[!PU>2`@&$(95M56(N%51.(4>=P#+
M5V+5EW^0T'X`EPA#,(=-<'^($&RGUX;E=H><MX0LZ'Q%(`B#&%U+B%TH%VZ#
M@'Y3H%<2H`C\YW^)0`$JIPB95VA;YXF+R`BM9WZ#<%F<%W_\=@`>%HLM^%0O
M&(R8YGO/)@C3I@@4Z%;4IP@JZ(*+D`9=IXP+UHR,D(HL6(6<-_\&L78$->!>
ME6>*V&@(UN<'M%5TE_<'D_94X)<(E.@')*@(U^4'5,`($J!S?D`$!'@(5\A[
MD+"-?B!H_\=Y:0"%&960@W"*@V"+U.B,1Q<B.M>)?S!P3V6!B0"%K@<)0\!K
M?E"-P$=YBO5Y?A!ZT!A[@U"0/L<#1!!?N/=^A'!Q(F>1T+9]DT5\@_`#@.>3
MAD"2Z\<(C?=42H4(GI=V0W@(!^=6-P>*@S`&J/4$%HA[2?@'5.E62=F`SS@(
MO&:'8#ETNV@(48!9;<"*B/`&O-8$/C9T+%D("(:'4GEARC8`'*>.2&AE'*B3
MA$")6I!"U]4&3H@(!MB1D^!\FJ<(8J?_9XL0;!Y8EV?6=H2`E1F'61-V?O$H
M"%&PC85YDY@5CFN&60K)"&PW68K0`,H6<87P!$#H!S>00L)("*_X5`I0")9Y
M"'_G5J7HE1=)"(UI4V&P/%BPC<LXE**6;9%PFHZG""BP:;>9"+7Y5`:VB0%9
M;X*`!D`(C+EI""B`9;9I"=;W<5,`GKV&G=UWC9/U1$"9:I1PE$%X8(`6EX*P
M;T9V"%.V!)')C,VUB]UI"$=H4YDI":86(M?5>X<PCT]E:QH(E4U9#H2W!%)'
M=DOHD8.P!\^WGW#F!_I9"+49G97I5B!*=KS6CWRVF8/`D1R:EQ.H:X?P`['6
M!M4I"3SICI`@_P'*5I2#8`#=U08:*0B#U:&$H`%Y!HQ_$*#W:0@U\)HZ&G3)
M1P@%>F%01U:(@`+;*(4:L&_O*&XI%@%*9II3>@2&YP/7)0!"20A!JJ'02`1-
M^@?69E-)2G)3.@$[&&T@H`!E^0=1*@@XV003=0@\D&)N4`1OA@(EL&,4H)Q5
MM``I=@'(&`D+T'5'0`4-L`(M0'A$,`!GBJ8<JJ9_,``*\*6#\*9%M@AO``)A
M*@<-,`13``41X`;590@:=WH_L&-^\&J(T%XQ5P(+,`5@T%UN0`6*J@AOD`04
MD'5N\%N5P`.M=WR>B@AIZIW85PBD&J<O.G$NJ):;UHE+>`1_:F5AH&V2A=:F
MB7".;J4"I4D)/U`"$[!C31`&7Q8)>\"J:CFL@H`%"9"O"?"9N%@'@CH!%/"H
M2JJO"9"G?_`#!%NPBV``'7`#K=8$+J")/A60#)`$?0<)&F``!K"IY/`&&LNQ
1MW``<["QF"`!6/"@C!`(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
